Literature DB >> 23111364

Conditional survival probabilities for patients with resected pancreatic adenocarcinoma.

Mark V Mishra1, Colin E Champ, Scott W Keith, Timothy N Showalter, Pramila R Anne, Yaacov Richard Lawrence, Voichita Bar-Ad.   

Abstract

BACKGROUND: The purpose of this study is to evaluate conditional survival probabilities for patients with resected pancreatic adenocarcinoma (PC).
METHODS: Patients with resected PC from 1998 to 2008 were identified from the Surveillance, Epidemiology and End Results Database. Data on patient, tumor, and treatment characteristics were extracted. Overall survival (OS) rates were calculated using the Kaplan-Meier method. A multivariable analysis at different time points from survival was performed to determine independent prognostic factors associated with all-cause mortality hazard ratios using Cox proportional hazards models.
RESULTS: A total of 4883 patients with resected PC were identified. The 1-, 3-, and 5-year survival estimates for patients at diagnosis were 67%, 29%, and 21%, respectively. The probability of surviving an additional 1-, 3-, or 5-year conditional upon already surviving 5 years after diagnosis were 89%, 76%, and 71%, respectively. Prognostic factors significantly correlated with improved OS at the time of diagnosis on multivariable analysis include: earlier stage, younger age, later year of diagnosis, white ethnicity, female sex, and residence in a high income district (P<0.05). Among those already surviving 3 years after diagnosis, younger age was the only prognostic factor statistically significantly correlated with improved OS (P<0.05).
CONCLUSIONS: Conditional survival estimates provide additional prognostic information that may be used to counsel PC patients on how their prognosis may change over time. Further research using prospectively collected data is warranted to help determine recommended follow-up intervals and benchmarks for future clinical trials.

Entities:  

Mesh:

Year:  2014        PMID: 23111364     DOI: 10.1097/COC.0b013e31826c62b7

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  4 in total

1.  Targeting Tumor Metabolism With Statins During Treatment for Advanced-stage Pancreatic Cancer.

Authors:  Nick A Iarrobino; Beant Gill; Mark E Bernard; Mark V Mishra; Colin E Champ
Journal:  Am J Clin Oncol       Date:  2018-11       Impact factor: 2.339

2.  Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy.

Authors:  Theodoros Michelakos; Yurie Sekigami; Filippos Kontos; Carlos Fernández-Del Castillo; Motaz Qadan; Vikram Deshpande; David T Ting; Jeffrey W Clark; Colin D Weekes; Aparna Parikh; David P Ryan; Jennifer Y Wo; Theodore S Hong; Jill N Allen; Onofrio Catalano; Andrew L Warshaw; Keith D Lillemoe; Cristina R Ferrone
Journal:  J Gastrointest Surg       Date:  2021-01-26       Impact factor: 3.452

3.  Conditional Survival After Resection for Pancreatic Cancer: A Population-Based Study and Prediction Model.

Authors:  Anouk E J Latenstein; Stijn van Roessel; Lydia G M van der Geest; Bert A Bonsing; Cornelis H C Dejong; Bas Groot Koerkamp; Ignace H J T de Hingh; Marjolein Y V Homs; Joost M Klaase; Valery Lemmens; I Quintus Molenaar; Ewout W Steyerberg; Martijn W J Stommel; Olivier R Busch; Casper H J van Eijck; Hanneke W M van Laarhoven; Johanna W Wilmink; Marc G Besselink
Journal:  Ann Surg Oncol       Date:  2020-02-12       Impact factor: 5.344

4.  Preoperative Clinical and Computed Tomography (CT)-Based Nomogram to Predict Oncologic Outcomes in Patients with Pancreatic Head Cancer Resected with Curative Intent: A Retrospective Study.

Authors:  Shin Hye Hwang; Ha Yan Kim; Eun Ju Lee; Ho Kyoung Hwang; Mi-Suk Park; Myeong-Jin Kim; Woo Jung Lee; Yong Eun Chung; Chang Moo Kang
Journal:  J Clin Med       Date:  2019-10-21       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.